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Background. Intermittent claudication due to peripheral artery disease (PAD) can be treated conservatively, or by
revascularization.
Objectives. To assess the short-term outcome of conservatively-treated claudicants, and determine predictors for clinical
improvement.
Design. A retrospective cohort study.
Methods. We evaluated Fontaine stage, walking distance and ankle brachial index (ABI) at baseline and after median 9
months (interquartile range (IQR) 6–24) in 181 patients with severe claudication.
Results. We found clinical improvement by at least one Fontaine stage in 38 patients (21%) with an increased walking
distance from baseline median 100 m (IQR 50–150) to follow-up median 650 m (IQR 300 to unlimited; p , 0.001), but
without changes in ABI (median 0.57, IQR 0.48–0.73 vs. median 0.54, IQR 0.45–0.81; p ¼ 0.10). One hundred and thirty-
eight patients (76%) remained clinically and hemodynamically stable. A worsening of the clinical stage but without
amputation was recorded in five patients (3%). Female gender (hazard ratio (HR) 0.51, p ¼ 0.052), diabetes (HR 0.35,
p ¼ 0.020), and baseline ABI below 0.44 (HR 0.31, p ¼ 0.019) were associated with a reduced probability of clinical
improvement.
Conclusion. Certain patients with intermittent claudication show substantial clinical improvement with conservative
medical therapy, despite any lack of hemodynamic improvement. Given the low number of patients with clinical
deterioration in the short term, primarily conservative therapy should be the preferred initial option for most claudicants.
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Introduction
Peripheral artery disease (PAD) is a serious medical
problem in industrialized countries1 and an indicator
of systemic atherosclerosis. Symptomatic patients with
intermittent claudication can be treated conservatively
by risk factor modification and physical training,2,3 or
by revascularization.4 – 6 Percutaneous balloon angio-
plasty and stenting are minimally-invasive procedures
that have a high immediate success rate4,7,8 and low
rate of complications.9,10 However, reocclusions after
initially successful treatment frequently occur.6,11 – 15
Conservative or so-called ‘best medical’ treatment
possess neither acute complications or immediate
beneficial effects. Yet, exercise training, especially
when supervised,16 can lead to durable symptomatic
improvement in patients with intermittent claudica-
tion2,17 – 22 by substantially increasing the walking
distance,22 and favorably altering the cardiovascular
risk factor profile.2,3,23,24 However, the indications for
interventional or conservative therapy are matter of an
ongoing debate:4,7,9,13,14,25 Randomized controlled
trials17,26 and meta-analyses suggest equal efficacy in
the long-term. The TransAtlantic Intersociety Consen-
sus (TASC) on the Management of Peripheral Artery
Disease6 and recent studies14,27 recommend a primar-
ily conservative approach for patients with claudica-
tion. Our retrospective cohort study was designed to
analyze the short-term results of conservative therapy
in patients with intermittent claudication, and to
identify predictors of clinical improvement.
Material and Methods
Study design
We enrolled patients with PAD Fontaine stage IIb6
(severe claudication with a maximum walking dis-
tance below 200 m) who attended our institutional
Eur J Vasc Endovasc Surg 27, 254–258 (2004)
doi: 10.1016/j.ejvs.2003.12.005, available online at http://www.sciencedirect.com on
*Corresponding author. Dr M. Schillinger, MD, Department of
Internal Medicine II, Division of Angiology, Vienna General
Hospital, Medical School, Waehringer Guertel 18-20, A-1090
Vienna, Austria.
1078–5884/030254 + 05 $35.00/0 q 2003 Elsevier Ltd. All rights reserved.
out-patient ward from January 1997 to December 2002
and were recommended for primary conservative
treatment at their initial presentation.
Patients
We screened more than 10 000 patients from our out-
patient ward for the diagnosis of peripheral artery
disease by review of original discharge letters and the
out-patient ward database. Of all these patients with
PAD Fontaine stage I (asymptomatic), IIa (walking
distance above 200 m), III (ischemic rest pain) and IV
(ischemic ulcers) were excluded. Furthermore,
patients with previous or planned iliofemoral or
femoropopliteal revascularization, either surgical or
interventional, were excluded. In patients with bilat-
eral disease, the clinically worse limb was considered
for all analyses, each patient thus was included only
once in the calculations. Thus, we identified 214
eligible patients with severe intermittent claudication
Fontaine stage IIb at least of one lower limb. Thirty-
three of 214 patients (15%) were excluded due to
missing follow-up data, leaving 181 eligible patients.
The median age of the study population was 71 years
(IQR 60 –76) and 92 patients (51%) were male.
Demographic data and the clinical characteristics of
the 181 patients are given in Table 1. Conservative
treatment included risk factor modification and
recommendations regarding physical training by
systematic walking for at least 60 min daily. However,
supervised physical training was not performed.
Baseline data
We recorded the Fontaine stage,6 walking distance (as
reported by the patients), ankle brachial index (ABI)
and arterial waveform (oscillography) of both limbs.
In patients with significant mediasclerosis, defined as
discrepancy between high ABI and low arterial wave-
forms, toe pressures at the first toe were obtained to
calculate ABIs. Localization and length of the lesions
were obtained by color-coded duplex sonography or
magnetic resonance imaging (MRI). Because patients
were routinely evaluated with serial non-invasive
testing at our out-patients department, changes in
the ABI and waveforms on pulse volume recordings
(PVRs) were available for comparison with the
symptomatic changes reported by the patients.
Definitions
Diabetes mellitus was defined according to the criteria
of the American Diabetes Association and was
assumed to be present in patients with a history of
diabetes taking anti-diabetic medication. Arterial
hypertension was diagnosed in patients with resting
blood pressure values above 140/90 mmHg, and was
assumed to be present in patients with a history of
hypertension taking anti-hypertensive drugs. Coron-
ary artery disease, according to the Canadian Cardi-
ovascular Society (CCS) classification, was evaluated
by treadmill exercise testing, dobutamin echocardio-
graphy, myocardial scintigraphy, and coronary angio-
graphy in selected cases.
Follow-up
Patients were followed by systematic chart review, and
review of the original evaluation protocols. Routinely,
patients were evaluated every 6 months with respect
to clinical deterioration or improvement, including a
physical examination and ABI and PVR measure-
ments. However, patients were also advised to
immediately attend the out-patient ward in case of
worsening of the symptoms as indicated by reduced
walking distance, rest pain or ulceration.
Table 1. Demographic data and clinical characteristics of the 181
patients with severe intermittent claudication (Fontaine stage IIb)
Risk factors
Body mass index (kg/m2) 27.1 (24.1–29.4)
Diabetes mellitus 69 (38%)
Arterial hypertension 129 (71%)
Hyperlipidemia 111 (61%)
Smoking 72 (40%)
Comorbidities
Coronary artery disease (CCS stage)
CCS I 47 (26%)
CCS II 24 (13%)
CCS III 4 (2%)
Carotid stenosis .25% 54 (30%)
Medication
Acetyl salicyl acid (100 mg daily) 142 (79%)
Clopidogrel (75 mg (daily) 12 (7%)
Phenprocoumon 24 (13%)
Statins 69 (38%)
Peripheral artery disease
Location of disease
Aorto-iliac arteries 34 (19%)
Femoro-popliteal arteries 120 (66%)
Multivessel 27 (15%)
ABI affected limb 0.55 (0.44–0.69)
Maximum walking distance 100 (50–150)
ABI contralateral limb 0.77 (0.55–0.93)
Fontaine stage contralateral limb
0 27 (15%)
I 9 (5%)
IIa 11 (6%)
IIb 134 (74%)
CCS denotes Canadian Cardiovascular Society.
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Study endpoints
The endpoint was the occurrence of clinical improve-
ment or worsening of conservatively treated patients
with severe intermittent claudication during follow-
up, and the identification of factors associated with
these clinical changes. The course of the clinical stage
(changes were defined by at least one stage in the
Fontaine classification), ABI, maximum walking dis-
tance, occurrence of critical limb ischemia, limb loss or
need for emergency revascularization were outcome
measures for evaluation of the primary study
endpoint.
Statistical methods
Continuous data are given as the median and
interquartile range (range from the 25th to the 75th
percentile). Discrete data are presented as counts and
percentages. We used Chi-square tests to compare
groups of categorical data and to test for trends.
Mann–Whitney U tests were applied to compare
groups of unpaired continuous data and Wilcoxon
paired tests used to analyze repeated measurements.
Multivariate Cox proportional hazards models were
used to assess factors associated with clinical improve-
ment of PAD. The results of the Cox proportional
hazards model are given as the hazard ratio (HR) and
the 95% confidence interval (95% CI). Additionally, an
ROC (receiver operator curve) analysis was applied to
determine the best cut-off of ABI for predicting clinical
failure of improvement. A two sided p-value ,0.05
was considered statistically significant. Calculations
were performed using MS Excel for Windows 2000,
SPSS for Windows (Version 10.0, SPSS Inc., IL, USA)
and Stata (release 8, Texas, USA).
Results
At baseline all 181 patients had Fontaine stage IIb.
At the time of follow-up after median 9 months (IQR
6–24) 18 patients (10%) had become asymptomatic, 20
patients (11%) had Fontaine stage IIa (walking
distance above 200 m), 138 patients (76%) had Fon-
taine stage IIb (walking distance below 200 m), four
patients (2%) had Fontaine stage III (ischemic rest
pain), and one patient (1%) had Fontaine stage 4
(ischemic ulcer). Overall, 38 patients (21%) showed a
clinical improvement, 138 patients (76%) remained
stable and a worsening of the clinical stage was
recorded in five patients (3%). In none of the patients,
was an amputation due to critical limb ischemia
required during follow-up. Ipsilateral endovascular
revascularisation was subsequently performed in 68
patients (37%) (67 patients with stable symptoms and
one patient with clinical deterioration). Four patients
(2%) with worsening symptoms underwent femoro-
popliteal bypass surgery. The maximum walking
distance was median 100 m (IQR 50–150) at baseline
and median 100 m (IQR 50–200) at the time of follow-
up ðp ¼ 0:002Þ: Twenty-nine (42%) of 69 patients with
diabetes had mediasclerosis as indicated by reduced
arterial compressibility during ABI measurements. In
these patients, toe arterial pressures instead of tibial
artery measurements were obtained at baseline and
follow-up. ABI remained widely unchanged with
median 0.55 (IQR 0.44–0.69) at the affected limb at
baseline and median 0.54 (IQR 0.41–0.70) at follow-up
ðp ¼ 0:39Þ: Walking distance and ABI of patients with
clinical improvement, stable claudication and clinical
deterioration by at least one Fontaine stage are given in
Table 2. Remarkably, although the walking distance in
patients with clinical improvement increased 6.5-fold,
the ABI remained largely unchanged (Table 2).
We then performed a multivariate Cox proportional
hazards analysis to determine factors independently
associated with clinical improvement, and to adjust for
possible confounding variables (Table 3). Female
patients, patients with diabetes, and patients with a
lower baseline ABI had a reduced probability of
clinical improvement, adjusting for age (in tertiles),
hypertension, smoking and location of the disease.
Vice versa, male gender, non-diabetics as well as
patients with higher ABI (above 0.44) were indepen-
dent predictors of clinical improvement. Addressing
the potentially best cut-off of ABI values for predicting
failure of clinical improvement, ROC analysis and
multivariate Cox models were applied revealing a best
cut-off of 0.44 (Table 3).
Analyzing potential confounders for the association
between gender and clinical improvement, we found
that demographic data and clinical characteristics (as
listed in Table 1) were equally balanced (all p-values
.0.2) between male and female patients with excep-
tion to the frequency of current smokers (male 44/72;
49% vs. female 28/72; 32%; p ¼ 0:017). However,
testing for interaction between gender, smoking habits
and clinical outcome by means of log likelihood ratio
Chi-square tests we found no significant effect
modification for a multiplicative interaction term
(smoking * gender), suggesting that gender was
associated with clinical outcome independent of
smoking status.
We analyzed the potential effects of clopidogrel and
statins with respect to clinical outcome as well as with
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respect to changes in ABI but we did not find any
significant association.
Discussion
We found a substantial symptomatic improvement in
21% of patients with initially severe claudication,
although hemodynamic measurements remained
widely unchanged. Female patients, diabetics, and
patients with a lower ABI at study entry had a reduced
probability for symptomatic improvement. Neverthe-
less, the rate of patients with worsening symptoms
was low, and limb loss was not observed in this cohort
of claudicants.
Our findings suggest that intermittent claudication
can be considered as a life-style limiting condition
rather than an immediate threat to limbs, confirming
previous studies.28,29 Claudicants therefore may be
considered for conservative treatment including risk
factor modification and physical training in the first
instance. Revascularization can be offered as a
secondary option in patients without or with insuffi-
cient improvement. Remarkably, the ABI even in
patients with significant improvement of symptoms
did not substantially change. One may speculate that
the underlying causes that exert beneficial effects on
walking distance may be an increased subjective
tolerance of exercise-induced ischemic pain, improve-
ment of the individual walking technique and optim-
ization of cellular oxygen consumption (similar to the
effects of training in athletes), factors which may be
mutually not exclusive.
Female gender, diabetes mellitus, and lower base-
line ABI were associated with a reduced probability of
clinical improvement. Diabetes and lower ABI are well
recognized as risk factors for progression of PAD28,30,31
and frequently are associated with multi-vessel dis-
ease. Therefore, a reduced rate of clinical improvement
in these patients is not unexpected. Although pre-
viously described,28 it is less clear why women had a
worse outcome. Nevertheless, it has to be acknowl-
edged that female gender showed only a borderline
significant association with outcome, leaving some
uncertainty due to the small patient numbers.
Previous studies4,26showed no major difference in
the outcome of conservatively or interventionally
treated patients, (assessed by maximum walking
distance and quality of life after a period of 2 years),
with restenosis remaining the major limitation of
angioplasty. Nevertheless, given the advanced age
and the relatively high short-term mortality of patients
with intermittent claudication,32,33 symptomatic
improvement even for only one or two years may
justify interventional treatment in patients suffering
from severe life-style limitations. Other studies,34,35
suggest that claudicants who initially report only a
small deterioration in quality of life have only a
modest gain in quality of life by invasive therapy.
Nevertheless, if severe symptoms and deterioration of
quality of life are reported, revascularization should be
considered.
We are aware of several limitations of this study.
The documentation of walking distance as reported by
the patients is debatable. Values at baseline and
follow-up may be prone to reporting bias, a limitation
which may be overcome by standardized walking tests
or treadmill exercise testing, which unfortunately was
not available in these patients. Objective testing of
walking distance is particularly necessary for com-
parative studies between interventional and conserva-
tive therapy. Nevertheless, symptoms reported by the
patients can be considered as the most important
trigger for considering revascularization in claudi-
cants. Our results therefore display data of immediate
clinical relevance obtained in a real-life setting. In this
study, the effect of ‘best medical treatment’ probably
reflects the grade of patients’ compliance in an
unattended setting and may underestimate the effect
of physical training. Other study limitations are a lack
of data on patients’ smoking status during follow-up
Table 2. Comparison of maximum walking distance and ABI in
patients with clinical improvement, stable claudication and
clinical deterioration by at least one Fontaine stage at baseline
and after median 9 months follow-up (IQR 6–24)
Baseline Follow-up P-value
Patients with stable claudication (n ¼ 138)
Walking distance 100 (50–150) 100 (50–150) 0.20
ABI 0.55 (0.44–0.68) 0.55 (0.41–0.70) 0.72
Patients with clinical improvement (n ¼ 38)
Walking distance 100 (50–150) 650 (300–1) ,0.001
ABI 0.57 (0.48–0.73) 0.54 (0.45–0.81) 0.10
Patients with clinical deterioration (n ¼ 5)
Walking distance 50 (30–100) –* ,0.001
ABI 0.46 (0.35–0.74) 0.33 (0.28–0.39) 0.03
Data are given as median and interquartile range (IQR: range from
the 25th to the 75th percentile).
*Ischemic rest pain.
Table 3. Cox proportional hazards model to assess the probability
of clinical improvement by at least one Fontaine stage
Hazard ratio 95% Confidence interval P-value
Female patients 0.51 0.25–1.00 0.052
Diabetes mellitus 0.35 0.15–0.87 0.020
ABI below 0.44 0.31 0.13–0.85 0.019
Adjusting for age (in tertiles), hypertension, smoking and location of
atherosclerotic lesions (aortoiliac, femoropopliteal, multi-segment).
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and the patients’ compliance with regular physical
training.
In conclusion, a significant proportion of patients
with intermittent claudication improve substantially
with conservative medical therapy, despite a lack of
hemodynamic improvement. Given the low number of
patients with clinical deterioration in the short term,
primarily conservative therapy should be the pre-
ferred initial option for most claudicants.
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